Concepts (158)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Deep Brain Stimulation | 5 | 2020 | 71 | 1.660 |
Why?
|
| Sirtuin 1 | 1 | 2022 | 47 | 0.830 |
Why?
|
| Metabolic Diseases | 1 | 2022 | 37 | 0.810 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 163 | 0.750 |
Why?
|
| Parkinson Disease | 3 | 2020 | 272 | 0.680 |
Why?
|
| Bone Wires | 1 | 2016 | 8 | 0.570 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2016 | 85 | 0.540 |
Why?
|
| Device Removal | 1 | 2016 | 100 | 0.520 |
Why?
|
| Neurosurgical Procedures | 1 | 2016 | 98 | 0.510 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2015 | 86 | 0.480 |
Why?
|
| Reward | 1 | 2015 | 201 | 0.460 |
Why?
|
| Brain Injuries | 1 | 2016 | 268 | 0.440 |
Why?
|
| Neoplasms | 1 | 2022 | 1667 | 0.380 |
Why?
|
| Depressive Disorder, Major | 2 | 2015 | 439 | 0.350 |
Why?
|
| Prefrontal Cortex | 2 | 2016 | 640 | 0.330 |
Why?
|
| Functional Laterality | 1 | 2010 | 240 | 0.320 |
Why?
|
| Subthalamic Nucleus | 2 | 2020 | 16 | 0.310 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2017 | 446 | 0.210 |
Why?
|
| Homeostasis | 2 | 2022 | 291 | 0.200 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2015 | 782 | 0.180 |
Why?
|
| Electrodes, Implanted | 2 | 2017 | 98 | 0.170 |
Why?
|
| Vitamin D Deficiency | 1 | 2022 | 292 | 0.170 |
Why?
|
| Sitagliptin Phosphate | 1 | 2018 | 4 | 0.160 |
Why?
|
| Humans | 20 | 2022 | 68618 | 0.160 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2018 | 15 | 0.160 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2018 | 14 | 0.160 |
Why?
|
| Protective Agents | 1 | 2018 | 36 | 0.160 |
Why?
|
| Glucocorticoids | 1 | 2020 | 222 | 0.150 |
Why?
|
| Brain Waves | 1 | 2018 | 30 | 0.150 |
Why?
|
| Electromagnetic Fields | 1 | 2018 | 66 | 0.150 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2018 | 84 | 0.150 |
Why?
|
| Thalamus | 1 | 2018 | 82 | 0.150 |
Why?
|
| B7-H1 Antigen | 1 | 2017 | 30 | 0.150 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 41 | 0.150 |
Why?
|
| Brain Neoplasms | 2 | 2014 | 371 | 0.140 |
Why?
|
| Sternum | 1 | 2016 | 19 | 0.140 |
Why?
|
| Dura Mater | 1 | 2016 | 23 | 0.140 |
Why?
|
| Middle Aged | 11 | 2020 | 21147 | 0.140 |
Why?
|
| Transcranial Direct Current Stimulation | 1 | 2018 | 111 | 0.130 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 1 | 2016 | 29 | 0.130 |
Why?
|
| Inflammation | 1 | 2022 | 1030 | 0.130 |
Why?
|
| Treatment Outcome | 4 | 2020 | 7029 | 0.130 |
Why?
|
| Apathy | 1 | 2015 | 28 | 0.130 |
Why?
|
| Psychotic Disorders | 1 | 2017 | 157 | 0.130 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2015 | 88 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 511 | 0.120 |
Why?
|
| Electric Stimulation Therapy | 1 | 2016 | 147 | 0.120 |
Why?
|
| Tumor Burden | 1 | 2014 | 132 | 0.120 |
Why?
|
| Quality of Life | 1 | 2022 | 1515 | 0.120 |
Why?
|
| Radiosurgery | 1 | 2014 | 66 | 0.120 |
Why?
|
| Male | 12 | 2020 | 37321 | 0.110 |
Why?
|
| Radiotherapy, Conformal | 1 | 2013 | 24 | 0.110 |
Why?
|
| Roma | 2 | 2010 | 3 | 0.110 |
Why?
|
| Salvage Therapy | 1 | 2013 | 82 | 0.110 |
Why?
|
| Adult | 10 | 2022 | 21403 | 0.110 |
Why?
|
| Quality Improvement | 2 | 2014 | 413 | 0.110 |
Why?
|
| Gene Frequency | 2 | 2010 | 207 | 0.100 |
Why?
|
| Polymorphism, Genetic | 2 | 2010 | 301 | 0.100 |
Why?
|
| Electroconvulsive Therapy | 1 | 2017 | 402 | 0.100 |
Why?
|
| Radiation Dosage | 1 | 2014 | 419 | 0.100 |
Why?
|
| Guideline Adherence | 1 | 2013 | 287 | 0.090 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 2010 | 18 | 0.090 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2010 | 22 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 1085 | 0.090 |
Why?
|
| Aged | 9 | 2020 | 14862 | 0.090 |
Why?
|
| Gastrointestinal Tract | 1 | 2010 | 63 | 0.090 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2009 | 11 | 0.080 |
Why?
|
| Mixed Function Oxygenases | 1 | 2009 | 35 | 0.080 |
Why?
|
| Genetics, Population | 1 | 2009 | 21 | 0.080 |
Why?
|
| Haplotypes | 1 | 2009 | 174 | 0.080 |
Why?
|
| Liver Diseases | 1 | 2010 | 193 | 0.080 |
Why?
|
| Female | 11 | 2020 | 38074 | 0.080 |
Why?
|
| Mixed Connective Tissue Disease | 1 | 2008 | 9 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 3259 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2010 | 333 | 0.080 |
Why?
|
| Calcium | 2 | 2018 | 929 | 0.070 |
Why?
|
| Neuropsychological Tests | 1 | 2010 | 517 | 0.070 |
Why?
|
| Sarcoidosis | 1 | 2008 | 77 | 0.070 |
Why?
|
| Prostatic Neoplasms | 1 | 2013 | 778 | 0.070 |
Why?
|
| Brain Mapping | 1 | 2010 | 532 | 0.070 |
Why?
|
| Anticoagulants | 1 | 2009 | 356 | 0.070 |
Why?
|
| Genotype | 4 | 2010 | 786 | 0.070 |
Why?
|
| Ceruloplasmin | 1 | 2005 | 8 | 0.070 |
Why?
|
| Ganglioglioma | 1 | 2005 | 11 | 0.070 |
Why?
|
| CA-19-9 Antigen | 1 | 2004 | 5 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2010 | 2223 | 0.060 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 4848 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 1851 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 134 | 0.050 |
Why?
|
| Cholecalciferol | 1 | 2022 | 143 | 0.050 |
Why?
|
| Dyskinesias | 1 | 2020 | 8 | 0.050 |
Why?
|
| Hungary | 2 | 2010 | 10 | 0.050 |
Why?
|
| Thyroid Hormones | 1 | 2020 | 31 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2022 | 332 | 0.040 |
Why?
|
| Alleles | 2 | 2010 | 386 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2020 | 145 | 0.040 |
Why?
|
| Receptors, Calcitonin Gene-Related Peptide | 1 | 2018 | 2 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2004 | 561 | 0.040 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2018 | 17 | 0.040 |
Why?
|
| TRPV Cation Channels | 1 | 2018 | 17 | 0.040 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2017 | 43 | 0.040 |
Why?
|
| Vitamin D | 1 | 2022 | 516 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2018 | 102 | 0.040 |
Why?
|
| Prevalence | 1 | 2022 | 1619 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 349 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1054 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 151 | 0.030 |
Why?
|
| Epidural Space | 1 | 2016 | 15 | 0.030 |
Why?
|
| Young Adult | 3 | 2016 | 5717 | 0.030 |
Why?
|
| Insulin | 1 | 2020 | 619 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 306 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2020 | 1738 | 0.030 |
Why?
|
| Organs at Risk | 1 | 2013 | 9 | 0.030 |
Why?
|
| Femur Head | 1 | 2013 | 17 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2013 | 32 | 0.030 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2013 | 30 | 0.030 |
Why?
|
| Rectum | 1 | 2013 | 62 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2013 | 36 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 756 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2013 | 125 | 0.030 |
Why?
|
| Europe | 1 | 2013 | 196 | 0.030 |
Why?
|
| Biomarkers | 1 | 2018 | 1593 | 0.030 |
Why?
|
| Urinary Bladder | 1 | 2013 | 108 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 2013 | 138 | 0.030 |
Why?
|
| Prostate | 1 | 2013 | 116 | 0.030 |
Why?
|
| Observer Variation | 1 | 2013 | 330 | 0.030 |
Why?
|
| Myocardium | 1 | 2018 | 1204 | 0.030 |
Why?
|
| Phantoms, Imaging | 1 | 2013 | 189 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2013 | 177 | 0.030 |
Why?
|
| Radiography | 1 | 2013 | 572 | 0.030 |
Why?
|
| Risk Factors | 1 | 2022 | 5731 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2014 | 622 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 2550 | 0.020 |
Why?
|
| India | 1 | 2010 | 41 | 0.020 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2010 | 37 | 0.020 |
Why?
|
| Rats | 1 | 2018 | 5300 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2010 | 137 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2010 | 238 | 0.020 |
Why?
|
| Cytochrome P-450 CYP2C9 | 1 | 2009 | 5 | 0.020 |
Why?
|
| Vitamin K Epoxide Reductases | 1 | 2009 | 4 | 0.020 |
Why?
|
| Population Groups | 1 | 2009 | 16 | 0.020 |
Why?
|
| Algorithms | 1 | 2014 | 1196 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2009 | 220 | 0.020 |
Why?
|
| Granuloma | 1 | 2008 | 21 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2008 | 99 | 0.020 |
Why?
|
| DNA | 1 | 2009 | 597 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2009 | 627 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 2800 | 0.020 |
Why?
|
| Receptors, Calcium-Sensing | 1 | 2004 | 10 | 0.020 |
Why?
|
| Brain | 1 | 2014 | 2176 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 1174 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2010 | 3705 | 0.010 |
Why?
|
| Animals | 1 | 2018 | 20881 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2004 | 508 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2004 | 1465 | 0.010 |
Why?
|
| Prognosis | 1 | 2004 | 2093 | 0.010 |
Why?
|
| Infant | 1 | 2005 | 2891 | 0.010 |
Why?
|
| Adolescent | 1 | 2009 | 8912 | 0.010 |
Why?
|